Pharmaceutical industry: latest news

Pharmaceutical industry features

Pharmaceutical industry news from aidsmap

More news

Pharmaceutical industry news selected from other sources

  • Martin Shkreli walks back on pledge to lower price of HIV drug Daraprim

    Shkreli’s company Turing Pharmaceuticals announced on Wednesday that it would provide volume discounts of its drug Daraprim to hospitals, but it appears that the company’s $750-a-pill price tag still stands.

    26 November 2015 | The Guardian
  • Pricing Pressures: How the Business of Medicine Affects the Price of Therapy

    Through a series of interviews with HCV Next, the manufacturers addressed the basics of how they arrived at the price for the drugs and combinations. Insurance experts discussed the specifics of coverage and how the Affordable Care Act is changing the game. Payers offered insight on their own role in the increasingly competitive arena.

    16 November 2015 | Healio HCV Next
  • U.S. FDA approves new indications for Harvoni®, Gilead’s once-daily single tablet regimen for chronic hepatitis C

    Label expanded to include patients with genotypes 4, 5 and 6 and patients co-infected with HIV.

    13 November 2015 | Gilled press release
  • High Cost of HIV Meds, Other Drugs Should Be Top Presidential Concern, Most Americans Say

    Rising drug costs, particularly for medications that treat chronic infections such as HIV, will likely be a hot-button issue during the 2016 presidential election cycle, according to a new poll from Kaiser Family Foundation (KFF). The survey reveals strong support across party lines for governmental action to ensure that drugs are affordable for those who need them.

    11 November 2015 | The Body
  • 'Significant Victory' as Gilead Expands Co-Pay Assistance for Truvada as PrEP

    Gilead Sciences announced its Truvada as PrEP co-pay assistance program will cover a total annual benefit of $3,600 with no monthly limit, according to Gilead spokesperson Ryan McKeel. The new program is effective November 6.

    06 November 2015 | Poz
  • FDA approves new treatment for HIV

    The U.S. Food and Drug Administration today approved Genvoya (a fixed-dose combination tablet containing elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide) as a complete regimen for the treatment of HIV-1 infection in adults and pediatric patients 12 years of age and older.

    06 November 2015 | FDA press release
  • Why are HIV meds so expensive, and what can we do about it?

    While the Daraprim example does not fully represent the story of why so many HIV and hepatitis C drugs carry such high price tags, the case brings up complicated, and controversial, questions of how drugs are priced. Why do Americans and their insurers pay more for some drugs and less for others? And who decides what a fair price for a drug should be, and how can manufacturers and health plans be compelled to improve access and affordability?

    29 October 2015 | BETA blog
  • GlaxoSmithKline beats sales forecasts thanks to HIV drugs boost

    The company said the standout performance was the 65% increase in sales of its HIV drugs, which GSK held on to in May after ditching plans to spin off the business.

    28 October 2015 | The Guardian
  • Gilead hepatitis C drug sales trend flattens, shares dip

    Gilead Sciences Inc on Tuesday said its quarterly profit rose 70 percent, but sales growth for its hepatitis C drugs flattened as health insurers limited access to the expensive treatments.

    28 October 2015 | Reuters
  • South Africa should override patent on key HIV medicine after widespread stock out problem

    After six months of persistent supply problems with the key HIV medicine lopinavir/ritonavir (LPV/r), the international medical humanitarian organisation Doctors Without Borders (MSF) urged the South African government to put the public’s health first and override pharmaceutical company AbbVie’s patent with a ‘compulsory licence,’ in order to allow generic versions of LPV/r to be used in the country.

    27 October 2015 | MSF
More news

Our information levels explained

  • Short and simple introductions to key HIV topics, sometimes illustrated with pictures.
  • Expands on the previous level, but also written in easy-to-understand plain language.
  • More detailed information, likely to include medical and scientific language.
  • Detailed, comprehensive information, using medical and specialised language.